Replimune Group (NASDAQ:REPL) was upgraded by research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued to investors on Friday, The Fly reports.
Several other research firms have also recently commented on REPL. Wedbush cut their price target on Eiger Biopharmaceuticals from $43.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 24th. HC Wainwright set a $73.00 price objective on Uniqure and gave the company a “buy” rating in a research note on Monday. Finally, Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Six research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $24.67.
NASDAQ:REPL opened at $13.13 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 14.26 and a current ratio of 14.26. Replimune Group has a one year low of $8.88 and a one year high of $23.55. The stock has a 50-day simple moving average of $13.57. The firm has a market capitalization of $441.08 million and a PE ratio of -9.87.
A number of hedge funds and other institutional investors have recently made changes to their positions in REPL. New York State Common Retirement Fund acquired a new stake in Replimune Group during the fourth quarter valued at approximately $65,000. BlackRock Inc. raised its stake in Replimune Group by 79.9% during the fourth quarter. BlackRock Inc. now owns 716,242 shares of the company’s stock valued at $7,164,000 after buying an additional 318,115 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Replimune Group by 21.2% during the fourth quarter. Bank of New York Mellon Corp now owns 24,049 shares of the company’s stock valued at $240,000 after buying an additional 4,209 shares in the last quarter. Northern Trust Corp raised its stake in Replimune Group by 2.5% during the fourth quarter. Northern Trust Corp now owns 81,234 shares of the company’s stock valued at $813,000 after buying an additional 2,014 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Replimune Group by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 52,687 shares of the company’s stock valued at $526,000 after buying an additional 6,878 shares in the last quarter. Hedge funds and other institutional investors own 59.58% of the company’s stock.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Featured Article: Front-End Load
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.